Johnson & Johnson (JNJ) shares experienced volatility despite a strong Q2 earnings beat and an upward revision of its full-year 2026 guidance. While the stock initially saw modest gains, it later declined as the company's MedTech unit missed market expectations. This price action reflects investor reaction to the contrast between overall financial strength and specific segment underperformance.
